ZFP52 Inhibitors
Chemical inhibitors of ZFP52 function through various mechanisms to disrupt signaling pathways essential for its activity. PD 98059, U0126, and SL327 act upstream by targeting MEK1/2 within the MAPK/ERK pathway. These inhibitors prevent the phosphorylation and activation of ERK, which is necessary for the downstream signaling that activates ZFP52. SB203580 takes a different approach by inhibiting p38 MAPK, another kinase within the MAPK family, which may also influence ZFP52 activity. By blocking the activity of p38 MAPK, SB203580 alters the signaling dynamics that contribute to the regulation of ZFP52. LY294002 and Wortmannin exert their effects by inhibiting PI3K, a pivotal kinase in the PI3K/Akt pathway. The inhibition of PI3K by these compounds reduces Akt activation, which in turn can affect the functional state of ZFP52. Rapamycin, by inhibiting mTOR, disrupts a different kinase pathway that can regulate ZFP52, demonstrating the complex interplay of cellular signaling in controlling protein functions.
Further illustrating the diverse regulatory landscape of ZFP52, Y-27632 targets ROCK kinase, which is implicated in the organization of the actin cytoskeleton, a process that can influence the activity of ZFP52. PP2 and Dasatinib are inhibitors of the Src family kinases and Abl, which are involved in multiple signaling pathways that can regulate ZFP52. By inhibiting these kinases, PP2 and Dasatinib affect the signaling networks that ZFP52 relies on. BAY 11-7082 disrupts ZFP52 activity by inhibiting NF-κB, a transcription factor that can regulate the expression of proteins including ZFP52. Lastly, SP600125 targets JNK, another member of the MAPK signaling pathways, and its inhibition can interfere with the signaling pathways that control ZFP52, leading to a decrease in its activity. Each of these chemicals, by targeting specific kinases and pathways, can influence the biological function of ZFP52.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 inhibits MEK, which is upstream of ERK in the MAPK signaling pathway. Since ZFP52 is regulated by MAPK signaling, inhibition of MEK by PD 98059 prevents the phosphorylation and subsequent activation of ZFP52. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 selectively inhibits MEK1/2, impeding the MAPK/ERK pathway. The activity of ZFP52 is dependent on this pathway, and by blocking MEK1/2, U0126 inhibits the activation of ZFP52. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
As an inhibitor of MEK1/2, SL327 disrupts the MAPK/ERK signaling cascade. Given that ZFP52 activity is contingent on this cascade, SL327’s action results in the functional inhibition of ZFP52. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 targets p38 MAPK, thereby inhibiting its activity. ZFP52, which may be regulated by p38 MAPK-mediated signaling, is functionally inhibited when this kinase's activity is blocked. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. PI3K is part of the PI3K/Akt pathway which can control ZFP52 activity. By inhibiting PI3K, LY294002 reduces Akt activation, leading to inhibition of ZFP52 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, and it prevents PI3K-mediated Akt phosphorylation. ZFP52, being regulated by the PI3K/Akt pathway, is functionally inhibited by the action of Wortmannin. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, Rapamycin interferes with the mTOR pathway, which can regulate proteins such as ZFP52. Inhibition of mTOR by Rapamycin leads to the inhibition of ZFP52 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits ROCK, which is involved in actin cytoskeleton organization. ZFP52 activity can be affected by cytoskeletal dynamics, so inhibition of ROCK by Y-27632 results in functional inhibition of ZFP52. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases. These kinases are involved in signaling pathways that regulate ZFP52. Inhibiting Src with PP2 thus leads to the functional inhibition of ZFP52. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib serves as a broad inhibitor of Src family kinases and Abl. By inhibiting these kinases, Dasatinib can suppress the signaling pathways that are necessary for the activation and function of ZFP52. | ||||||